Northern Capital Management LLC boosted its stake in OvaScience Inc. (NASDAQ:OVAS) by 61.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,340 shares of the company’s stock after buying an additional 11,500 shares during the period. Northern Capital Management LLC’s holdings in OvaScience were worth $158,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Orbis Allan Gray Ltd bought a new stake in shares of OvaScience during the first quarter worth approximately $19,839,000. JPMorgan Chase & Co. increased its position in OvaScience by 2.8% in the first quarter. JPMorgan Chase & Co. now owns 341,789 shares of the company’s stock worth $3,243,000 after buying an additional 9,350 shares during the last quarter. Geode Capital Management LLC increased its position in OvaScience by 9.1% in the first quarter. Geode Capital Management LLC now owns 164,168 shares of the company’s stock worth $1,557,000 after buying an additional 13,699 shares during the last quarter. Stoneridge Investment Partners LLC increased its position in OvaScience by 120.4% in the second quarter. Stoneridge Investment Partners LLC now owns 49,960 shares of the company’s stock worth $260,000 after buying an additional 27,291 shares during the last quarter. Finally, FNY Managed Accounts LLC acquired a new position in OvaScience during the second quarter worth about $208,000. 80.70% of the stock is currently owned by institutional investors and hedge funds.
Shares of OvaScience Inc. (NASDAQ:OVAS) traded up 4.61% during mid-day trading on Monday, hitting $7.49. 352,801 shares of the company were exchanged. The company’s market capitalization is $266.35 million. OvaScience Inc. has a 12-month low of $4.53 and a 12-month high of $15.39. The firm has a 50 day moving average of $6.79 and a 200 day moving average of $7.18.
OvaScience (NASDAQ:OVAS) last released its earnings results on Thursday, August 4th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.16. OvaScience had a negative return on equity of 60.10% and a negative net margin of 13,906.35%. The firm had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.21 million. During the same quarter in the previous year, the business posted ($0.64) earnings per share. The business’s revenue for the quarter was up 530.0% on a year-over-year basis. Equities research analysts forecast that OvaScience Inc. will post ($2.66) earnings per share for the current year.
OVAS has been the topic of a number of research reports. JPMorgan Chase & Co. cut their target price on shares of OvaScience from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Friday, August 5th. JMP Securities restated a “neutral” rating on shares of OvaScience in a research report on Wednesday, August 10th. Credit Suisse Group AG restated a “sell” rating on shares of OvaScience in a research report on Tuesday, July 12th. Finally, Zacks Investment Research upgraded shares of OvaScience from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research report on Wednesday, August 10th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $10.31.
OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.
Want to see what other hedge funds are holding OVAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OvaScience Inc. (NASDAQ:OVAS).
Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.